nach oben

Neurotoxicity Research

Erschienen in:

01.01.2019 | ORIGINAL ARTICLE

Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients

verfasst von: Sunee Sirivichayakul, Buranee Kanchanatawan, Supaksorn Thika, André F. Carvalho, Michael Maes

Erschienen in: Neurotoxicity Research | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Abstract

Eotaxin is increased in neurodegenerative disorders and schizophrenia, and preclinical studies indicate that eotaxin may induce cognitive deficits. This study aims to examine whether peripheral levels of eotaxin impact cognitive functioning in healthy volunteers and formal thought disorder (FTD) and psychopathology in schizophrenia patients. Serum levels of eotaxin were assayed and cognitive tests were performed on a sample of 40 healthy participants and 80 schizophrenia patients. Among healthy participants, eotaxin levels were significantly associated with episodic/semantic memory, executive functions, Mini Mental State Examination, emotion recognition, and sustained attention. In addition, age-related effects on these cognitive measures were partly mediated by eotaxin. The super-variable “age-eotaxin” predicted a large part of the variance in cognitive functions among healthy participants, and hence, eotaxin may act as an “accelerated brain aging chemokine” (ABAC). In schizophrenia, eotaxin levels had a strong impact on formal thought disorders and psychopathology. In schizophrenia, increased eotaxin strongly impacts memory and sustained attention, which together to a large extent determine FTD. FTD together with memory deficits predicts around 92.5% of the variance in psychopathology. Moreover, the effects of eotaxin are partially mediated by executive functioning, while the effects of male sex on FTD and psychopathology are mediated by eotaxin. In healthy subjects, eotaxin strongly impacts executive functioning and multiple cognitive domains. In schizophrenia, peripheral levels of eotaxin strongly impact both negative symptoms and psychosis (hallucinations and delusions), and these eotaxin effects are mediated by impairments in frontal functioning, memory, sustained attention, and FTD. Eotaxin is an endogenous cognitive deteriorating chemokine (ECDC) and a novel therapeutic target for age-related cognitive decline and schizophrenia as well.

Adar T, Shteingart S, Ben Ya’acov A, Bar-Gil Shitrit A, Goldin E (2014) From airway inflammation to inflammatory bowel disease: eotaxin-1, a key regulator of intestinal inflammation. Clin Immunol 153(1):199–208PubMedCrossRef

Adzemovic MZ, Öckinger J, Zeitelhofer M, Hochmeister S, Beyeen AD, Paulson A, Gillett A, Thessen Hedreul M, Covacu R, Lassmann H, Olsson T, Jagodic M (2012) Expression of Ccl11 associates with immune response modulation and protection against neuroinflammation in rats. PLoS One 7(7):e39794PubMedPubMedCentralCrossRef

Andreasen NC (1989) The scale for the assessment of negative symptoms (SANS): conceptual and theoretical foundations. Br J Psychiatry 155(Suppl 7):49–58CrossRef

Andreasen NC, Grove WM (1986) Thought, language, and communication in schizophrenia: diagnosis and prognosis. Schizophr Bull 12(3):348–359PubMedCrossRef

Andreasen NC, Olsen S (1982) Negative v positive schizophrenia. Definition and validation. Arch Gen Psychiatry 39(7):789–794PubMedCrossRef

Ayer A, Yalınçetin B, Aydınlı E, Sevilmiş Ş, Ulaş H, Binbay T, Akdede BB, Alptekin K (2016) Formal thought disorder in first-episode psychosis. Compr Psychiatry 70:209–215PubMedCrossRef

Bachman P, Cannon TD (2012) In: Holyoak KJ, Morrison RG (eds) The cognitive neuroscience of thought disorder in schizophrenia. The Oxford handbook of thinking and reasoning. Oxford University Press, New York. https://doi.org/10.1093/oxfordhb/9780199734689.013.0034 CrossRef

Baddeley AD (2002) Is working memory still working? Eur Psychol 7(2):85–97CrossRef

Baruch K, Ron-Harel N, Gal H, Deczkowska A, Shifrut E, Ndifon W, Mirlas-Neisberg N, Cardon M, Vaknin I, Cahalon L, Berkutzki T, Mattson MP, Gomez-Pinilla F, Friedman N, Schwartz M (2013) CNS-specific immunity at the choroid plexus shifts toward destructive Th2 inflammation in brain aging. Proc Natl Acad Sci U S A 110(6):2264–2269PubMedPubMedCentralCrossRef

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289–300

Berberian AA, Moraes GV, Gadelha A, Brietzke E, Fonseca AO, Scarpato BS, Vicente MO, Seabra AG, Bressan RA, Lacerda AL (2016) Is semantic verbal fluency impairment explained by executive function deficits in schizophrenia? Rev Bras Psiquiatr 38(2):121–126PubMedCrossRef

Bettcher BM, Fitch R, Wynn MJ, Lalli MA, Elofson J, Jastrzab L, Mitic L, Miller ZA, Rabinovici GD, Miller BL, Kao AW, Kosik KS, Kramer JH (2016) MCP-1 and eotaxin-1 selectively and negatively associate with memory in MCI and Alzheimer’s disease dementia phenotypes. Alzheimers Dement (Amst) 3:91–97

Bleuler E (1911–1950) Dementia Praecox, or the group of schizophrenias. (1911) Translated by J. Zinkin. New York: International Universities Press, 1950

Butcher L, Peres K, Andre P, Walter S, Dartigues J, Rodriguez-Manas L, Feart C, Erusalimsky JD (2017) Cognitive status is associated with CCL11 in older rural dwellers: findings from the FRAILOMIC study. Innovation in Aging 1(suppl_1):595PubMedCentralCrossRef

CANTAB (2018) The most validated cognitive research software. www.cambridgecognition.com/cantab

CERAD (1986) CERAD—an overview: the consortium to establish a registry for Alzheimer’s disease. http://cerad.mc.duke.edu/

Cherry JD, Stein TD, Tripodis Y, Alvarez VE, Huber BR, Au R, Kiernan PT, Daneshvar DH, Mez J, Solomon TM, Alosco ML, McKee AC (2017) CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer’s disease. PLoS One 12(9):e0185541PubMedPubMedCentralCrossRef

Corlett PR, Murray GK, Honey GD, Aitken MR, Shanks DR, Robbins TW, Bullmore ET, Dickinson A, Fletcher PC (2007) Disrupted prediction-error signal in psychosis: evidence for an associative account of delusions. Brain 130(Pt 9):2387–2400PubMedCrossRef

Erickson MA, Morofuji Y, Owen JB, Banks WA (2014) Rapid transport of CCL11 across the blood-brain barrier: regional variation and importance of blood cells. J Pharmacol Exp Ther 349(3):497–507PubMedPubMedCentralCrossRef

Frith CD, Blakemore S, Wolpert DM (2000) Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Brain Res Rev 31(2–3):357–363PubMedCrossRef

Frydecka D, Krzystek-Korpacka M, Lubeiro A, Stramecki F, Stańczykiewicz B, Beszłej JA, Piotrowski P, Kotowicz K, Szewczuk-Bogusławska M, Pawlak-Adamska E, Misiak B (2018) Profiling inflammatory signatures of schizophrenia: a cross-sectional and meta-analysis study. Brain Behav Immun 71:28–36PubMedCrossRef

Fusar-Poli P, Deste G, Smieskova R, Barlati S, Yung AR, Howes O, Stieglitz RD, Vita A, McGuire P, Borgwardt S (2012) Cognitive functioning in prodromal psychosis: a meta-analysis. Arch Gen Psychiatry 69(6):562–571PubMedCrossRef

Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE, Alzheimer’s Disease Neuroimaging Initiative (2011) Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer’s disease neuroimaging initiative. Arch Gen Psychiatry 68(9):961–969PubMedCrossRef

Häfner H (2003) Gender differences in schizophrenia. Psychoneuroendocrinology 28(Suppl 2):17–54PubMedCrossRef

Hamilton M (1959) The assessment of anxiety states by rating. Br J Med Psychol 32:50–55PubMedCrossRef

Harvey PD, Koren D, Reihenberg A, Bowie CR (2006) Negative symptoms and cognitive deficits: what is the nature of their relationship? Schizophr Bull 32:250–258PubMedCrossRef

Hepworth MR, Hardman MJ, Grencis RK (2010) The role of sex hormones in the development of Th2 immunity in a gender-biased model of Trichuris muris infection. Eur J Immunol 40(2):406–416PubMedCrossRef

Hoefer J, Luger M, Dal-Pont C, Culig Z, Schennach H, Jochberger S (2017) The “aging factor” eotaxin-1 (CCL11) is detectable in transfusion blood products and increases with the donor’s age. Front Aging Neurosci 9:402PubMedPubMedCentralCrossRef

Kanchanatawan B, Hemrungrojn S, Thika S, Sirivichayakul S, Ruxrungtham K, Carvalho AF, Geffard M, Anderson G, Maes M (2018a) Changes in tryptophan catabolite (TRYCAT) pathway patterning are associated with mild impairments in declarative memory in schizophrenia and deficits in semantic and episodic memory coupled with increased false-memory creation in deficit schizophrenia. Mol Neurobiol 55(6):5184–5201PubMedCrossRef

Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Kubera M, Maes M (2018b) Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis. https://doi.org/10.1007/s11011-018-0208-4

Kanchanatawan B, Sriswasdi S, Thika S, Stoyanov D, Sirivichayakul S, Carvalho AF, Geffard M, Maes M (2018c) Towards a new classification of stable phase schizophrenia into major and simple neuro-cognitive psychosis: results of unsupervised machine learning analysis. J Eval Clin Pract. https://doi.org/10.1111/jep.12945

Kanchanatawan B, Thika S, Anderson G, Galecki P, Maes M (2018d) Affective symptoms in schizophrenia are strongly associated with neurocognitive deficits indicating disorders in executive functions, visual memory, attention and social cognition. Prog Neuropsychopharmacol Biol Psychiatry 80(Pt C):168–176PubMedCrossRef

Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276PubMedCrossRef

Kerns JG, Berenbaum H (2003) The relationship between formal thought disorder and executive functioning component processes. J Abnorm Psychol 112(3):339–352PubMedCrossRef

Kircher T, Bröhl H, Meier F, Engelen J (2018) Formal thought disorders: from phenomenology to neurobiology. Lancet Psychiatry 5(6):515–526PubMedCrossRef

Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr (1989) The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119–123PubMedCrossRef

Kittirathanapaiboon P, Khamwongpin M (2005) The validity of the Mini International Neuropsychiatric Interview (M.I.N.I.) Thai version. Suanprung Hospital, Department of Mental Health, Chiang Mai

Lalli MA, Bettcher BM, Arcila ML, Garcia G, Guzman C, Madrigal L, Ramirez L, Acosta-Uribe J, Baena A, Wojta KJ, Coppola G, Fitch R, de Both MD, Huentelman MJ, Reiman EM, Brunkow ME, Glusman G, Roach JC, Kao AW, Lopera F, Kosik KS (2015) Whole-genome sequencing suggests a chemokine gene cluster that modifies age at onset in familial Alzheimer’s disease. Mol Psychiatry 20(11):1294–1300PubMedPubMedCentralCrossRef

Liddle PF (1987) Schizophrenic syndromes, cognitive performance and neurological dysfunction. Psychol Med 17(1):49–57PubMedCrossRef

Maes M, Meltzer HY, Bosmans E (1994) Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89(5):346–351PubMedCrossRef

Maes M, Meltzer HY, Buckley P, Bosmans E (1995) Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression. Eur Arch Psychiatry Clin Neurosci 244(6):325–329PubMedCrossRef

Maher B (1972) The language of schizophrenia: a review and interpretation. Br J Psychiatry 120:3–17PubMedCrossRef

McGrath JJ (1991) Ordering thoughts on thought disorder. Br J Psychiatry 158:307–316PubMedCrossRef

Mendelsohn AR, Larrick JW (2014) Systemic factors mediate reversible age-associated brain dysfunction. Rejuvenation Res 17(6):525–528PubMedCrossRef

Mochizuki M, Bartels J, Mallet AI, Christophers E, Schröder JM (1998) IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. J Immunol 160(1):60–68PubMed

Noto C, Ota VK, Gouvea ES, Rizzo LB, Spindola LM, Honda PH, Cordeiro Q, Belangero SI, Bressan RA, Gadelha A, Maes M, Brietzke E (2014) Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. Int J Neuropsychopharmacol 2014:18(4)

Noto C, Maes M, Ota VK, Teixeira AL, Bressan RA, Gadelha A, Brietzke E (2015a) High predictive value of immune-inflammatory biomarkers for schizophrenia diagnosis and association with treatment resistance. World J Biol Psychiatry 27:1–8

Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, Cordeiro Q, Belangero SI, Bressan RA, Gadelha A, Maes M, Brietzke E (2015b) Effects of depression on the cytokine profile in drug naïve first-episode psychosis. Schizophr Res 164(1–3):53–58PubMedCrossRef

Noto C, Ota VK, Santoro ML, Gouvea ES, Silva PN, Spindola LM, Cordeiro Q, Bressan RA, Gadelha A, Brietzke E, Belangero SI, Maes M (2016) Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic naïve first episode psychosis. Mol Neurobiol 53(8):5701–5709PubMedCrossRef

Orellana G, Slachevsky A (2013) Executive functioning in schizophrenia. Front Psychiatry 4:35PubMedPubMedCentralCrossRef

Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psycholog Rep 10:799–812CrossRef

Pedrini M, Massuda R, de Lucena D, Macêdo D, Paz AV, Lobato MI, Belmonte-de-Abreu PS, Ceresér KM, Rocha NP, Curra MD, Panizzutti BS, Teixeira AL, Gama CS (2014) Differences in eotaxin serum levels patients with recent onset and in chronic stable schizophrenia: a clue for understanding accelerating aging profile. Schizophr Res 152(2–3):528–529PubMedCrossRef

Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, Foster PS, Rothenberg ME (2001) IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. J Allergy Clin Immunol 108(4):594–601PubMedCrossRef

Ranganath C, Cohen MX, Brozinsky CJ (2005) Working memory maintenance contributes to long-term memory formation: neural and behavioral evidence. J Cogn Neurosci 17(7):994–1010PubMedCrossRef

Ringle CM, Wende S, Becker J-M (2015) SmartPLS 3. SmartPLS, Bönningstedt Retrieved from http://www.smartpls.com

Roche E, Lyne J, O'Donoghue B, Segurado R, Behan C, Renwick L, Fanning F, Madigan K, Clarke M (2016) The prognostic value of formal thought disorder following first episode psychosis. Schizophr Res 178(1–3):29–34PubMedCrossRef

Rostene W, Buckingham JC (2007) Chemokines as modulators of neuroendocrine functions. J Mol Endocrinol 38(3):351–353PubMedCrossRef

Roy-O’Reilly M, Ritzel RM, Conway SE, Staff I, Fortunato G, McCullough LD (2017) CCL11 (eotaxin-1) levels predict long-term functional outcomes in patients following ischemic stroke. Transl Stroke Res 8(6):578–584PubMedPubMedCentralCrossRef

Simpson DM, Davis GC (1985) Measuring thought disorder with clinical rating scales in schizophrenic and nonschizophrenic patients. Psychiatry Res 15:313–318PubMedCrossRef

Smagula SF, Karim HT, Lenze EJ, Butters MA, Wu GF, Mulsant BH, Reynolds CF, Aizenstein HJ (2017) Gray matter regions statistically mediating the cross-sectional association of eotaxin and set-shifting among older adults with major depressive disorder. Int J Geriatr Psychiatry 32(12):1226–1232PubMedCrossRef

Subotnik KL, Nuechterlein KH, Green MF, Horan WP, Nienow TM, Ventura J, Nguyen AT (2006) Neurocognitive and social cognitive correlates of formal thought disorder in schizophrenia patients. Schizophr Res 85(1–3):84–95PubMedCrossRef

Targowski T, Jahnz-Rózyk K, Plusa T, Glodzinska-Wyszogrodzka E (2005) Influence of age and gender on serum eotaxin concentration in healthy and allergic people. J Investig Allergol Clin Immunol 15(4):277–282PubMed

Teixeira AL, Reis HJ, Nicolato R, Brito-Melo G, Correa H, Teixeira MM, Romano-Silva MA (2008) Increased serum levels of CCL11/eotaxin in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(3):710–714CrossRef

Villeda SA, Luo J, Mosher KI, Zou B, Britschgi M, Bieri G, Stan TM, Fainberg N, Ding Z, Eggel A, Lucin KM, Czirr E, Park JS, Couillard-Després S, Aigner L, Li G, Peskind ER, Kaye JA, Quinn JF, Galasko DR, Xie XS, Rando TA, Wyss-Coray T (2011) The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 477(7362):90–94PubMedPubMedCentralCrossRef

Wainwright DA, Xin J, Mesnard NA, Politis CM, Sanders VM, Jones KJ (2009) Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice. J Neuroimmunol 216(1–2):66–75PubMedPubMedCentralCrossRef

Ying S, Robinson DS, Meng Q, Rottman J, Kennedy R, Ringler DJ, Mackay CR, Daugherty BL, Springer MS, Durham SR, Williams TJ, Kay AB (1997) Enhanced expression of eotaxin and CCR3 mRNA and protein in atopic asthma. Association with airway hyperresponsiveness and predominant co-localization of eotaxin mRNA to bronchial epithelial and endothelial cells. Eur J Immunol 27(12):3507–3516PubMedCrossRef

Yuan B, Chen J, Gong L, Shu H, Liao W, Wang Z, Liu D, Xie C, Zhang Z (2016) Mediation of episodic memory performance by the executive function network in patients with amnestic mild cognitive impairment: a resting-state functional MRI study. Oncotarget 7(40):64711–64725PubMedPubMedCentral

Zachrisson O, Regland B, Jahreskog M, Kron M, Gottfries CG (2002) A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale). J Psychosom Res 52:501–509PubMedCrossRef

Zhu C, Xu B, Sun X, Zhu Q, Sui Y (2017) Targeting CCR3 to reduce amyloid-β production, tau hyperphosphorylation, and synaptic loss in a mouse model of Alzheimer’s disease. Mol Neurobiol 54(10):7964–7978PubMedCrossRef

Titel: Eotaxin, an Endogenous Cognitive Deteriorating Chemokine (ECDC), Is a Major Contributor to Cognitive Decline in Normal People and to Executive, Memory, and Sustained Attention Deficits, Formal Thought Disorders, and Psychopathology in Schizophrenia Patients
verfasst von: Sunee Sirivichayakul
Buranee Kanchanatawan
Supaksorn Thika
André F. Carvalho
Michael Maes
Publikationsdatum: 01.01.2019
Verlag: Springer US
Erschienen in: Neurotoxicity Research / Ausgabe 1/2019
Print ISSN: 1029-8428
Elektronische ISSN: 1476-3524
DOI: https://doi.org/10.1007/s12640-018-9937-8

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2019

Blebbistatin, a Myosin II Inhibitor, Exerts Antidepressant-Like Activity and Suppresses Detrusor Overactivity in an Animal Model of Depression Coexisting with Overactive Bladder

DT-Diaphorase Prevents Aminochrome-Induced Lysosome Dysfunction in SH-SY5Y Cells

Exploring the Effect of Endoplasmic Reticulum Stress Inhibition by 4-Phenylbutyric Acid on AMPA-Induced Hippocampal Excitotoxicity in Rat Brain

Retinol-Binding Protein 4 Predicts Lesion Volume (Determined by MRI) and Severity of Acute Ischemic Stroke

Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro